AdCD40L—Crossing the Valley of Death?
Author:
Publisher
Informa UK Limited
Subject
Immunology,Immunology and Allergy
Link
http://www.tandfonline.com/doi/pdf/10.3109/08830185.2012.692844
Reference50 articles.
1. CD40L - A Multipotent Molecule for Tumor Therapy
2. The Janus faces of CD40 in cancer
3. Blocking the CD40L-CD40 interaction in vivo specifically prevents the priming of T helper 1 cells through the inhibition of interleukin 12 secretion.
4. Phase I Study of Recombinant Human CD40 Ligand in Cancer Patients
5. CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia
Cited by 18 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. The role of immune cells and immune related genes in the tumor microenvironment of papillary thyroid cancer and their significance for immunotherapy;Scientific Reports;2024-08-05
2. A phase I study of an adenoviral vector delivering a MUC1/CD40-ligand fusion protein in patients with advanced adenocarcinoma;Nature Communications;2022-10-28
3. Current development in adenoviral vectors for cancer immunotherapy;Molecular Therapy - Oncolytics;2021-12
4. Intratumoral immunostimulatory AdCD40L gene therapy in patients with advanced solid tumors;Cancer Gene Therapy;2020-12-14
5. Combination of Oncolytic Virotherapy and CAR T/NK Cell Therapy for the Treatment of Cancer;Molecular Biology;2020-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3